Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients
Stopped early · Phase 3
Conditions studied: Lung Transplantation, Lung Diseases
In brief
The purpose of this study is to quantify the dose of aerosol medication deposited in the lungs of lung transplant recipients receiving a single nebulized treatment of aerosolized Abelcet® (lipid complexed amphotericin-B). This study is being performed to determine the range of deposited doses and patterns of distribution that could be expected in this population so that the ultimate efficacy of this preparation can be evaluated. A radioisotope technique will be utilized to track the medication dose. The study will include 12 subjects who will perform one testing session lasting approximately 3 hours. An Investigational New Drug Application (IND) detailing this protocol has been submitted by the principal investigator (PI) and approved by the Food and Drug Administration \[FDA\] (72,521).
Key facts
- Study ID
- NCT00235651
- Run by
- University of Pittsburgh
- People needed
- 12
- Starts
- 2005-10-01
- Expected to finish
- 2006-04-01
- Last updated by the study team
- 2008-12-17
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Single or double lung transplant recipients
- Age > 18
- Willing to be available at the testing center
- Able to understand and complete informed consent
You may not qualify if…
- Pregnant women, or women capable of bearing children who will not perform urine pregnancy test.
- Nursing mothers.
- Hypersensitivity to amphotericin B (Abelcet®) or technetium [Tc-99m] based radiopharmaceuticals.
- Subjects with a past history of bronchospasm associated with aerosol drug use
- Subjects with active bacterial or viral infection as defined by the current use of non-prophylactic antibiotic anti-viral medications
- Subjects with an FEV1 < 30% predicted or forced vital capacity (FVC) % predicted < 30%
- Subjects requiring supplemental oxygen
- Receipt of inhalational or IV amphotericin B within last 30 days
- Subjects with known fungal infection, as per Mycoses Study Group (MSG) criteria, on therapy with antifungal drugs or diagnosed on the day of bronchoscopy
- Serum creatinine > 1.9 mg/dl on the day of clinic visit
- Liver enzymes ALT/AST/alk phos greater than two times the normal limit
- Concurrent intravenous aminoglycoside use
- Subjects with fever > 38.2°C
- Subjects on mechanical ventilation.
- Have participated in any studies involving radiopharmaceuticals within 14 days.
Where it is running
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.